Ultragenyx Pharmaceutical Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Ultragenyx Pharmaceutical Inc Unternehmen

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Ultragenyx Pharmaceutical Inc Informationen



BörsenkürzelRARE

Name des UnternehmensUltragenyx Pharmaceutical Inc

IPO-datumJan 31, 2014

CEOKakkis (Emil D)

Anzahl der mitarbeiter1294

WertpapierartOrdinary Share

GeschäftsjahresendeJan 31

Addresse60 Leveroni Ct

StadtNOVATO

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94949

Telefon14154838800

Websitehttps://www.ultragenyx.com/

BörsenkürzelRARE

IPO-datumJan 31, 2014

CEOKakkis (Emil D)

Führungskräfte von Ultragenyx Pharmaceutical Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.83M

+2.71%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

140.45K

+16.46%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

90.60K

+31.89%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

48.72K

-9.61%

Mr. Michael A. Narachi

Independent Director

26.95K

-1.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

26.95K

-1.47%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.20K

-1.96%

Dr. Amrit Ray, M.D.

Independent Director

17.63K

-2.24%

Mr. Matthew K. (Matt) Fust

Independent Director

--

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.83M

+2.71%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

140.45K

+16.46%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

90.60K

+31.89%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

48.72K

-9.61%

Mr. Michael A. Narachi

Independent Director

26.95K

-1.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

26.95K

-1.47%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Crysvita royalty revenue

304.00M

45.17%

Crysvita

177.00M

26.30%

Dojolvi

96.00M

14.26%

Evkeeza

59.00M

8.77%

Mepsevii

37.00M

5.50%

Nach RegionUSD

Name

Umsatz

Anteil

North America

377.00M

56.02%

Latin America

170.00M

25.26%

Europe Middle East and Africa

108.00M

16.05%

Asia Pacific

18.00M

2.67%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Crysvita royalty revenue

304.00M

45.17%

Crysvita

177.00M

26.30%

Dojolvi

96.00M

14.26%

Evkeeza

59.00M

8.77%

Mepsevii

37.00M

5.50%

Aktionärsstatistik

Aktualisiert: Sun, May 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Vanguard Portfolio Management, LLC

5.47%

BlackRock Institutional Trust Company, N.A.

5.47%

State Street Investment Management (US)

5.10%

Vanguard Capital Management, LLC

4.25%

Sands Capital Management, LLC

3.26%

Andere

76.45%

Aktionäre

Anteil

Vanguard Portfolio Management, LLC

5.47%

BlackRock Institutional Trust Company, N.A.

5.47%

State Street Investment Management (US)

5.10%

Vanguard Capital Management, LLC

4.25%

Sands Capital Management, LLC

3.26%

Andere

76.45%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

47.10%

Investment Advisor/Hedge Fund

25.80%

Hedge Fund

17.03%

Research Firm

4.75%

Individual Investor

3.79%

Sovereign Wealth Fund

1.28%

Venture Capital

0.51%

Pension Fund

0.44%

Bank and Trust

0.40%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

695

106.19M

107.82%

-1.32M

2025Q4

665

100.29M

103.96%

-2.21M

2025Q3

640

97.34M

100.90%

-3.53M

2025Q2

635

97.48M

101.32%

-2.63M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

5.07M

5.26%

+54.55K

+1.09%

Sep 30, 2025

State Street Investment Management (US)

3.69M

3.83%

+1.12M

+43.55%

Sep 30, 2025

Sands Capital Management, LLC

3.77M

3.91%

-173.63K

-4.40%

Sep 30, 2025

JP Morgan Asset Management

3.25M

3.37%

+644.31K

+24.74%

Sep 30, 2025

RTW Investments L.P.

3.26M

3.38%

+1.55M

+90.83%

Sep 30, 2025

Kakkis (Emil D)

2.69M

2.79%

-31.78K

-1.17%

Mar 07, 2025

Baker Bros. Advisors LP

2.77M

2.87%

--

Sep 30, 2025

Wellington Management Company, LLP

1.95M

2.02%

+73.31K

+3.92%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

Motley Fool Small-Cap Growth ETF

3.73%

Global X Genomics & Biotechnology ETF

3.19%

Franklin Genomic Advancements ETF

1.59%

Virtus LifeSci Biotech Products ETF

1.41%

State Street SPDR S&P Biotech ETF

1.32%

WisdomTree BioRevolution Fund

0.94%

Direxion Daily S&P Biotech Bull 3X Shares

0.81%

Touchstone Sands Capital US Select Growth ETF

0.8%

Goldman Sachs Future Health Care Equity ETF

0.6%

First Trust Multi-Manager Large Growth ETF

0.54%

Motley Fool Small-Cap Growth ETF

Anteil3.73%

Global X Genomics & Biotechnology ETF

Anteil3.19%

Franklin Genomic Advancements ETF

Anteil1.59%

Virtus LifeSci Biotech Products ETF

Anteil1.41%

State Street SPDR S&P Biotech ETF

Anteil1.32%

WisdomTree BioRevolution Fund

Anteil0.94%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.81%

Touchstone Sands Capital US Select Growth ETF

Anteil0.8%

Goldman Sachs Future Health Care Equity ETF

Anteil0.6%

First Trust Multi-Manager Large Growth ETF

Anteil0.54%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten